SCHEMBL915566 — predicted protein targets

Known targets — ChEMBL curated mechanism

ABL1 BMX BRAF BTK CHRNA4 CHRNB2 CSNK1E EGFR ERBB2 F10 FLT1 FLT3 FLT4 IGF1R INSR ITK JAK3 KDR KIT OPRM1 PARP1 PARP2 PDGFRB PIK3CD RAF1 RET SLC18A2 TEC TXK dacA dacB dacC ftsI mrcA mrcB mrdA rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	LMNA	P02545	7/20	0.48

▸	ALDH1A1	P00352	5/20	0.48

▸	HTT	P42858	3/20	0.48

▸	MAPT	P10636	7/20	0.48

▸	KDM4E	B2RXH2	4/20	0.48

▸	MEN1	O00255	3/20	0.48

▸	KMT2A	Q03164	3/20	0.48

▸	GAA	P10253	1/20	0.48

▸	SMN1; SMN2	Q16637	3/20	0.48

▸	HPGD	P15428	2/20	0.48

▸	TUBB4A	P04350	1/20	0.46

▸	TUBB	P07437	1/20	0.46

▸	TUBA3C	P0DPH7	1/20	0.46

▸	TUBA1B	P68363	1/20	0.46

▸	TUBA4A	P68366	1/20	0.46

▸	TUBB4B	P68371	1/20	0.46

▸	TUBB3	Q13509	1/20	0.46

▸	TUBB2A	Q13885	1/20	0.46

▸	TUBB8	Q3ZCM7	1/20	0.46

▸	TUBA3E	Q6PEY2	1/20	0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL915568	1.00	LMNA (0.48)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL916502	0.92	ALDH1A1 (0.48)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL916505	0.92	ALDH1A1 (0.48)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL914616	0.87	KMT2A (0.46)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL914619	0.87	KMT2A (0.46)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL2068590	0.86	PARP1 (0.44)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL2068589	0.86	PARP1 (0.44)	LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL915540	0.85	SMN1; SMN2 (0.52)	LMNAALDH1A1HTTMAPTMEN1
SCHEMBL915538	0.85	SMN1; SMN2 (0.52)	LMNAALDH1A1HTTMAPTMEN1
SCHEMBL915515	0.85	ALDH1A1 (0.52)	LMNAALDH1A1HTTMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20130295009-A1	METHOD OF TREATING INFLAMMATION	HPF IP HOLDING S.A. (LU)	2013-11-07	—	—	US	claimed
EP-1313461-A2	THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	Melacure Therapeutics AB (SE)	2003-05-28	—	—	EP	claimed
WO-2002011715-A2	THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	MELACURE THERAPEUTICS AB (SE)	2002-02-14	—	—	WO	claimed
US-9227927-B2	Method of treating inflammation	ANAMAR AB (SE)	2016-01-05	—	—	US	disclosed
US-20130295009-A1	METHOD OF TREATING INFLAMMATION	HPF IP HOLDING S.A. (LU)	2013-11-07	—	—	US	disclosed
US-20120178820-A1	METHOD FOR TREATING ARTHRITIS	ANAMAR AB (SE)	2012-07-12	—	—	US	disclosed
US-8148429-B2	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	ANAMAR AB (SE)	2012-04-03	—	—	US	disclosed
US-20110015437-A1	USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	ACURE PHARMA AB (SE)	2011-01-20	—	—	US	disclosed
US-20070231267-A1	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	ACURE PHARMA AB (SE)	2007-10-04	—	—	US	disclosed
US-20070088085-A1	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	MELACURE THERAPEUTICS AB (SE)	2007-04-19	—	—	US	disclosed
US-20040024060-A1	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	ACURE PHARMA AB (SE)	2004-02-05	—	—	US	disclosed
EP-1313461-A2	THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	Melacure Therapeutics AB (SE)	2003-05-28	—	—	EP	disclosed
WO-2002011715-A2	THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	MELACURE THERAPEUTICS AB (SE)	2002-02-14	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20070231267-A1	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	MC1R, MC5R, MCHR1	LMNA 4609/4885ALDH1A1 1879/4885HTT 333/4885
US-20040024060-A1	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	MC1R, MC5R, MCHR1	LMNA 4614/4885ALDH1A1 1756/4885HTT 336/4885
US-20070088085-A1	Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands	MC1R, MC5R, MCHR1	LMNA 4609/4885ALDH1A1 1879/4885HTT 333/4885
US-20110015437-A1	USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS	MC1R, MC5R, MCHR1	LMNA 4609/4885ALDH1A1 1879/4885HTT 333/4885
US-20130295009-A1	METHOD OF TREATING INFLAMMATION	MC2R, MC5R, MC1R	LMNA 3918/4885ALDH1A1 1930/4885HTT 1123/4885
US-20120178820-A1	METHOD FOR TREATING ARTHRITIS	MC5R, MC1R, MC2R	LMNA 4542/4885ALDH1A1 2132/4885HTT 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.